Cancer Res (2023) 83 (8_Supplement): LB031.

Abstract. The CD47-SIRPα axis functions as an immune checkpoint, transmitting a “don’t eat me” signal to prevent macrophage-mediated phagocytosis of tumor cells. While CD47 is expressed on most immune ...

Abstract. Auristatins are a class of clinically validated payloads used extensively in antibody-drug conjugate (ADC) technology. There are currently 4 FDA approved ADCs utilizing the vedotin drug ...

Abstract. Lipid metabolism reprogramming modulates the tumor microenvironment (TME) and alters the function of immune cells, including tumor-infiltrating lymphocytes (TIL). Although lipids can enhance ...

1Department of General Surgery, Zhongshan Hospital, Fudan University School of Medicine, Shanghai, China.

Neuronal pentraxin 1 (NPTX1) is identified as a therapeutically druggable driver of pancreatic cancer metastatic colonization through its action on the receptor AMIGO2, which promotes HIF-1α nuclear ...

1School of Medicine, University of California San Diego, La Jolla, California. *Corresponding Author: James T. Robinson, School of Medicine, University of California ...

Infrequently mutated genes comprise most of the mutational burden in breast tumors but are poorly understood. In vivo CRISPR screening identified functional tumor suppressors that converged on ...

1Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York.

The combination of anti-TROP2 ADCs with PD-(L)1 inhibitors represents a promising therapeutic strategy, merging targeted therapy with immunotherapy to improve treatment outcomes. Clinical trials are ...

Abstract. Molecular glue degrader (MGD) is an emerging therapeutic strategy offering an exciting alternative to traditional small molecules exploring new target space. These small molecules interact ...